Published in Clin Pharmacol Ther on January 01, 2005
Clinical significance of ABCB1 genotyping in oncology. J Oncol Pharm Pract (2009) 0.91
Imaging of multidrug resistance in cancer. Cancer Imaging (2011) 0.90
Evaluation of (99m)technetium-mebrofenin and (99m)technetium-sestamibi as specific probes for hepatic transport protein function in rat and human hepatocytes. Pharm Res (2010) 0.85
Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Sci Rep (2014) 0.81
ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib. Oncol Lett (2014) 0.78
Invertebrate models for coenzyme q10 deficiency. Mol Syndromol (2014) 0.77
Pharmacogenetics and outcome with antipsychotic drugs. Dialogues Clin Neurosci (2014) 0.76
Mathematical Simulation of Transport Kinetics of Tumor-Imaging Radiopharmaceutical (99m)Tc-MIBI. Comput Math Methods Med (2017) 0.75
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol (2011) 7.18
Progesterone induces adult mammary stem cell expansion. Nature (2010) 4.69
Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet (2009) 3.89
Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet (2008) 3.79
Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst (2002) 3.46
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature (2011) 2.96
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst (2002) 2.70
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40
A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer (2006) 2.35
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet (2011) 2.26
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med (2005) 2.26
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17
Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst (2010) 2.12
Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Res Treat (2013) 2.05
Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res (2006) 2.05
Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS (2011) 1.90
Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma. Int J Cancer (2011) 1.76
A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices. Arch Intern Med (2009) 1.74
Overlapping and distinct expression of progesterone receptors A and B in mouse uterus and mammary gland during the estrous cycle. Endocrinology (2006) 1.70
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res (2011) 1.65
Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res (2006) 1.64
Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion. J Invest Dermatol (2012) 1.63
Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination. J Clin Oncol (2006) 1.56
DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology (2009) 1.55
Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol (2006) 1.51
HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res (2010) 1.48
Ki67 and proliferation in breast cancer. J Clin Pathol (2013) 1.46
Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat Genet (2011) 1.46
Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol (2003) 1.45
Comment on "A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502d7 that demethylates codeine to morphine", J Biol Chem 279: 27383-27389. Drug Metab Dispos (2005) 1.38
Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res (2004) 1.36
Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol (2009) 1.30
Neurological evaluation of untreated human immunodeficiency virus infected adults in Ethiopia. J Neurovirol (2007) 1.30
HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Res Treat (2011) 1.29
Population-based, case-control-family design to investigate genetic and environmental influences on melanoma risk: Australian Melanoma Family Study. Am J Epidemiol (2009) 1.27
EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene (2003) 1.23
Monocular deprivation in adult mice alters visual acuity and single-unit activity. Learn Mem (2007) 1.21
BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res (2013) 1.18
A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet (2013) 1.17
The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet (2005) 1.14
Meta-analysis combining new and existing data sets confirms that the TERT-CLPTM1L locus influences melanoma risk. J Invest Dermatol (2011) 1.14
Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res (2009) 1.14
IGFBP7 is not required for B-RAF-induced melanocyte senescence. Cell (2010) 1.13
Galactose-α-1,3-galactose-specific IgE is associated with anaphylaxis but not asthma. Am J Respir Crit Care Med (2012) 1.12
Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genet Med (2009) 1.10
Molecular grading of ductal carcinoma in situ of the breast. Clin Cancer Res (2008) 1.09
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res (2008) 1.08
Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. Nucl Recept Signal (2009) 1.08
Irinotecan pharmacogenomics. Pharmacogenomics (2010) 1.07
The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a. Mol Cancer (2009) 1.06
Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chromosomes Cancer (2004) 1.05
Expression and transcriptional activity of progesterone receptor A and progesterone receptor B in mammalian cells. Breast Cancer Res (2002) 1.05
A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Mol Cancer Ther (2012) 1.04
Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Mol Cancer Ther (2011) 1.04
Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Mol Endocrinol (2005) 1.04
Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother (2010) 1.03
Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev (2010) 1.03
Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials (2010) 1.03
Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet (2003) 1.03
Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. Int J Cancer (2005) 1.02
Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing. Am J Surg Pathol (2006) 1.02
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. Am J Clin Oncol (2009) 1.01
Sample size determination for clinical trials with co-primary outcomes: exponential event times. Pharm Stat (2012) 1.00
MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecol Oncol (2005) 1.00
Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol (2012) 0.99
Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol (2009) 0.98
Hormone-responsive model of primary human breast epithelium. J Mammary Gland Biol Neoplasia (2009) 0.97
Anticipated uptake of genetic testing for familial melanoma in an Australian sample: An exploratory study. Psychooncology (2007) 0.97
Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer. Mol Endocrinol (2013) 0.97
p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors. Neoplasia (2008) 0.96
Copy number variants in pharmacogenetic genes. Trends Mol Med (2011) 0.96
A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. J Neurovirol (2011) 0.96
Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. PLoS One (2011) 0.96
A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). Eur J Cancer (2008) 0.95
Subnuclear distribution of progesterone receptors A and B in normal and malignant endometrium. J Clin Endocrinol Metab (2004) 0.95
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr (2007) 0.95
Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol (2004) 0.95
Inhibitors of mTOR. Oncologist (2010) 0.95
Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int (2013) 0.94
Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. Pathology (2009) 0.94
Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. Nutr Cancer (2003) 0.94
Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. J Steroid Biochem Mol Biol (2008) 0.93
Review and cross-validation of gene expression signatures and melanoma prognosis. J Invest Dermatol (2011) 0.93
Neurologic consequences of hepatitis C and human immunodeficiency virus coinfection. J Neurovirol (2005) 0.93